Teva and Sanofi present new outcome from Phase 2b study of duvakitug
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Subscribe To Our Newsletter & Stay Updated